What Ongoing Monitoring for Tysabri-Related PML Involves

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Exposure Concerns

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML) and what monitoring is needed. This page explains the typical follow-up tests, such as MRI scans and lumbar punctures, that help detect PML early. Building on decades of medical and legal experience, we provide clear, factual information to help you understand the monitoring process.

Bridging Patient Risk and Occupational Liability

The transition from general health information to specific exposure concerns is essential when therapeutic agents like Tysabri enter mass production settings. While patients receive Tysabri under controlled medical supervision with known risks, workers in manufacturing facilities may face unintended exposure through inhalation, dermal contact, or accidental needlestick. This occupational exposure pathway raises distinct legal questions, particularly regarding the statute of limitations for claims in Massachusetts. The bridge between legacy health education and mass production liability lies in recognizing that manufacturing environments transform therapeutic substances into potential occupational hazards, thereby shifting the burden of proof from clinical efficacy to workplace safety and long-term exposure monitoring. For individuals who develop Progressive Multifocal Leukoencephalopathy (PML) after occupational Tysabri exposure, understanding the medical evidence and legal time limits is critical.

Medical Evidence: Tysabri and PML Risk

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Massachusetts who have developed PML after Tysabri exposure, understanding the medical evidence and legal time limits is critical. The prescribing information for Tysabri contains a boxed warning stating that the drug increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, and the expected benefit must be weighed against the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinically, PML presents with progressive neurological deficits such as weakness, visual changes, cognitive decline, and coordination problems. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The label instructs healthcare professionals to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Importantly, PML has been reported even after Tysabri discontinuation in patients who had no findings suggestive of PML at the time of stopping the drug; therefore, monitoring should continue for at least six months after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism and Risk Factors for PML

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing JC virus reactivation and uncontrolled infection of oligodendrocytes. This immunosuppressive effect is particularly pronounced in patients with anti-JCV antibodies, as these antibodies indicate prior JC virus exposure and potential latency. The label explicitly states that PML typically occurs only in immunocompromised patients and that Tysabri-treated patients are at increased risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). From a risk perspective, the adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The boxed warning and the restricted TOUCH Prescribing Program were implemented to mitigate risk, but questions remain about whether patients and prescribers were fully informed of the PML risk, especially in the context of cumulative exposure and prior immunosuppressant use. For affected patients in Massachusetts, settlement considerations may include the severity of disability, duration of Tysabri therapy, and the presence of known risk factors at the time of treatment.

Statute of Limitations Considerations in Massachusetts

The timeline between Tysabri exposure and documented harm is variable. PML can develop months to years after starting therapy, with risk increasing after two years of treatment. The label notes that longer treatment duration, especially beyond two years, is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, PML can occur after Tysabri discontinuation, complicating the determination of when the harm was first manifest. For statute of limitations purposes in Massachusetts, the clock typically begins when the injury is discovered or reasonably should have been discovered. Given the insidious onset of PML symptoms and the potential for delayed diagnosis, patients should seek legal counsel promptly upon diagnosis. In summary, the medical evidence clearly establishes that Tysabri increases PML risk, with identifiable risk factors and a need for vigilant monitoring. For Massachusetts patients pursuing settlement, the statute of limitations will depend on the date of diagnosis or when the connection to Tysabri was recognized. Given the complexity of PML presentation and the potential for delayed recognition, timely legal consultation is essential.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Massachusetts?

In Massachusetts, the statute of limitations for personal injury claims generally is three years from the date the injury is discovered or reasonably should have been discovered. For PML, which may have a delayed onset, the clock typically starts when the patient is diagnosed or when the connection to Tysabri is recognized. It is crucial to consult an attorney promptly to preserve your rights.

What are the known risk factors for developing PML while on Tysabri?

The prescribing information identifies three key risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Can PML occur after stopping Tysabri?

Yes, PML has been reported even after Tysabri discontinuation in patients who had no findings suggestive of PML at the time of stopping the drug. Therefore, monitoring should continue for at least six months after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.